Does FGF23 toxicity influence the outcome of chronic kidney disease?
about
The FGF23-Klotho axis: endocrine regulation of phosphate homeostasisFGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?Dysregulation of phosphate metabolism and conditions associated with phosphate toxicityIn vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levelsFibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?Roles of major facilitator superfamily transporters in phosphate response in DrosophilaGenetic determinants of phosphate response in Drosophila.Phosphate sensing.Clinical Significance of FGF-23 in Patients with CKD.Osteo-renal regulation of systemic phosphate metabolism.Phosphate toxicity: new insights into an old problemMolecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho systemReversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylaseFibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.The FGF family: biology, pathophysiology and therapyThe role of Klotho in energy metabolism.Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.Can features of phosphate toxicity appear in normophosphatemia?Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.Vitamin D and immune function: an overview.Cardiovascular disease in chronic kidney disease: untying the Gordian knot.Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease.αKlotho and Chronic Kidney Disease.FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372[FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients.Dietary phosphate modifies lifespan in Drosophila.Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease.
P2860
Q24625902-A32EFEBC-5652-4F0A-AE57-4C4B61621CA4Q24653541-FCB78563-DA24-496D-A149-8C187B64B4B6Q28085476-6B4E57C9-47DA-48E0-9E42-1E07B59D8231Q33572351-29874FE2-91E6-4EAB-B529-2D1DFA365C15Q33904467-7C12A8AD-3A2A-40D6-8BB5-798B60286BBDQ34168361-68E993B5-0733-44C1-BD35-6E395BEF0FBFQ34631633-1BF88815-0DB5-46DE-84C8-1A9D63154990Q34690795-407BAE74-56C9-4C95-B5C6-0BAC75992FDCQ34989319-19C8E3E3-F153-4ED2-984F-2BE2573F27A1Q35059741-6B0F8C2E-60A5-4AF1-A529-41FC3A4678DAQ35059905-3347E8DA-9291-4C55-9E53-2B20CE8AA093Q35059924-E479C08B-CD19-483B-B935-7D923C06D6A0Q35126790-00A23BA7-B00A-4B9B-99CA-786599436D27Q35967107-C0E4FE6B-BF1C-496E-B909-46AF8A212568Q36933339-D7A77960-3EB4-414B-B759-4B4EF9EAE8A1Q36992839-E9841E30-967B-4E3C-8D3A-9F2E87E5648DQ37221997-24B7B395-360D-4F66-8E61-E437B050E51EQ37244863-2EFEAE1F-4BD5-4443-9602-79BA9E6A6A01Q37415834-3D5422BD-7B3D-4907-854B-45D1E3513701Q37919185-EF9FD858-CC48-48BD-AACC-92D204842DC6Q38025185-F728C584-9F69-463E-A03C-E9F4D7074CCEQ38049170-7734F3CE-E582-461F-8E91-BFF8C1EFA8F0Q38057137-1E4F04DC-5AA9-470E-84C6-D7A9641AEE33Q38076051-0968170B-4388-430D-86AD-49779D1CB771Q39812781-ADAB86BF-68ED-48F0-95A6-4A735D0EA0F0Q39866881-7A68C34A-CA4C-4BBF-8D04-934B8F812D4BQ41460824-C6229C97-5ECE-48C9-AFCA-41AAE8B3B606Q42529430-CC04005D-4C28-4480-8118-53795C366E00Q42878661-2A4C2569-27CF-434D-AC5D-3747E744D848Q43074642-AE3E4854-261C-4D0B-B956-D0211620516CQ46567248-301A1B38-87E1-4FF3-834C-91EA6652A48CQ52743002-B5300326-5E98-4566-8EEE-408A2C1402BEQ53149178-6908BEED-D30C-46AF-A310-2D86BADCBBE2
P2860
Does FGF23 toxicity influence the outcome of chronic kidney disease?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Does FGF23 toxicity influence the outcome of chronic kidney disease?
@en
Does FGF23 toxicity influence the outcome of chronic kidney disease?
@nl
type
label
Does FGF23 toxicity influence the outcome of chronic kidney disease?
@en
Does FGF23 toxicity influence the outcome of chronic kidney disease?
@nl
prefLabel
Does FGF23 toxicity influence the outcome of chronic kidney disease?
@en
Does FGF23 toxicity influence the outcome of chronic kidney disease?
@nl
P2860
P356
P1476
Does FGF23 toxicity influence the outcome of chronic kidney disease?
@en
P2093
Mohammed Shawkat Razzaque
P2860
P356
10.1093/NDT/GFN620
P407
P577
2008-11-07T00:00:00Z